Adding Dulaglutide, Liraglutide or Semaglutide (GLP-1 agonists) to existing treatment for type 2 diabetes has major cardiovascular benefits. Exenatide* and Lixisenatide were neutral for providing cardiovascular benefits.
Read More »
The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?
Read More »
The results of a recent phase III study may offer children with diabetes a new route for better glycemic control.
Read More »
The use of GLP-1 receptor agonists in patients may prevent multiple risks.
Read More »
Unique directions for taking the pill may cause a compliance issue; it's not as simple as just taking a pill once a day.
Read More »
Efpeglenatide, a new GLP-1 receptor agonist, referenced to liraglutide in Phase II trial.
Read More »
Final results from a phase 3 study preceded FDA approval of oral semaglutide.
Read More »
A secondary analysis of the LEADER trial to investigate the safety of liraglutide in patients with type 2 diabetes.
Read More »
A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin.
Read More »
Exenatide joins trend of GLP-1 agonists showing benefit for patients with established CVD.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.